Public disclosure of clinical trial results at Clinical Trial Registry of India- Need for transparency in research!
Perspectives in Clinical Research · 2023-04 · 14 (2) · 81-85
DOI: 10.4103/picr.picr_39_22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Perspectives in Clinical Research, online erschienen am 14.11.2022. Verfasst von Renuka Munshi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, T. N. Medical College and BYL Nair Ch., Hospital, Mumbai, Maharashtra, India. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Since June 15, 2009, clinical trial registration in the Clinical Trial Registry-India (CTRI) has been made mandatory by the Drugs Controller General of India to improve transparency, accountability, conform to accepted ethical standards and reporting of all relevant results of registered trials. In this study, we planned to evaluate the compliance of Indian and global sponsors with clinical trials conducted in India in terms of reporting of clinical trial results at the CTRI.
Methods
We included trials registered in the CTRI between January 2018 and January 2020. The CTRI and ClinicalTrials.gov registry was thoroughly searched for all completed interventional studies. A year-wise comparative analysis was performed to evaluate the number of clinical trials reporting results in both the registry.
Results
The reporting of completed interventional clinical trial results was 25/112 (22.32%) in year 2018, y, 8/105 (7.6%) in year 2019 and 17/140 (12.14%) in year 2020. There was significantly less reporting of results of Pharmaceutical company sponsored Interventional Studies-Indian at CTRI when compared with ClinicalTrials.gov registry for the year 2019 (odds ratio [OR]-0.17 (95% confidence interval [CI]: 0.08–0.36) and P < 0.0001) and year 2020 (OR-0.45 [95% CI: 0.24–0.82] and P < 0.01). The difference in results reported at CTRI was significantly low for Pharmaceutical company sponsored Interventional Studies-Global only for year 2019 (OR-0.09 [95% CI: 0.005–1.45] and P = 0.04) compared with ClinicalTrials.gov.
Conclusion
There is a need to develop the culture of reporting clinical trial results in CTRI to strengthen the transparency in the research for overall benefit of public, health care professionals, and research community.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, T. N. Medical College and BYL Nair Ch., Hospital, Mumbai, Maharashtra, India.
Zitieren
APA
Munshi, R., Pilliwar, C., & Maurya, M. R. (2023). Public disclosure of clinical trial results at Clinical Trial Registry of India- Need for transparency in research!. Perspectives in Clinical Research, 14(2), 81-85. https://doi.org/10.4103/picr.picr_39_22
Vancouver
Munshi R, Pilliwar C, Maurya MR. Public disclosure of clinical trial results at Clinical Trial Registry of India- Need for transparency in research!. Perspectives in Clinical Research. 2023;14(2):81-85. doi:10.4103/picr.picr_39_22
BibTeX
@article{Munshi2023,
author = {Munshi, Renuka and Pilliwar, Chaitali and Maurya, Miteshkumar Rajaram},
title = {Public disclosure of clinical trial results at Clinical Trial Registry of India- Need for transparency in research!},
journal = {Perspectives in Clinical Research},
year = {2023},
volume = {14},
number = {2},
pages = {81--85},
doi = {10.4103/picr.picr_39_22}
}
EUVIMED